期刊名称：EXPERIMENTAL HEMATOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Experimental Hematology publishes original research reports, reviews, letters to the editor, and abstracts of the annual meeting of the International Society for Experimental Hematology. We welcome manuscripts describing research involving in vivo and ex vivo studies in the following areas: cell cycle regulation, cytokines, erythropoiesis, gene therapy, general hematopoiesis, granulopoiesis, hematological malignancies, immunobiology, immunotherapy, lymphopoiesis, megakaryocytopoiesis, microenvironment, monocyte development, molecular genetics, signal transduction, stem cell biology, and experimental as well as clinical stem cell transplantation.
Audience
Hematologists, Oncologists, Transfusion Scientists, Immunologists, Cell Biologists and Marrow Transplanters
Abstracting / Indexing
- BIOSIS
- Chemical Abstracts
- Current Contents
- EMBASE
- Index Medicus
Instructions to Authors
REVIEW PROCESS
Experimental Hematology welcomes submissions in the categories listed below. Each submitted manuscript will undergo peer review by at least two editorial board members or other experts designated by the editor-in-chief or associate editor in charge of the manuscript's review. Authors' names will be seen by reviewers, but reviewers' names will not be disclosed to the authors. A paper can be rejected without undergoing the peer review process if the editor determines that the content is inappropriate for the journal. Authors usually receive the editorial decision within 4 weeks of their manuscript's arrival at the editorial office.
Halftones and color photographs (glossy figures) of rejected manuscripts will be returned to the corresponding author. Rejected manuscripts will not be returned. The editoral office acknowledges receipt of manuscripts within 10 days of receipt.
Papers submitted by editors or editorial board members are subjected to the same rigorous standards as other manuscripts. An editor who submits a manuscript for consideration does not have access to the reviewers' identities or their confidential remarks for that submission.
Regular Submissions: These are full-length reports of original research involving in vivo and ex vivo studies in the following areas: cell cycle regulation, cytokines, erythropoiesis, gene therapy, general hematopoiesis, granulopoiesis, hematological malignancies, immunobiology, immunotherapy, lymphopoiesis, megakaryocytopoiesis, microenvironment, monocyte development, molecular genetics, signal transduction, stem cell biology, and experimental as well as clinical stem cell transplantation.
We also welcome reports on stem cell plasticity, including those involving stem cells from sources other than marrow and blood. We welcome studies regarding the phenotype and growth factor requirements of stem cells; studies addressing homing and engraftment as well as functional reconstitution of stem cells; and fundamental investigations regarding the nature of transdifferentiation and dedifferentiation.
Rapid Communications: Papers submitted as Rapid Communications must report original, complete, and definitive information of particular significance to the field, will undergo an expedited review, and, if accepted, will be published at an earlier date than regularly submitted manuscripts. The letter accompanying the manuscript must briefly explain the nature and significance of the observations and specifically request review as a rapid full-length communication. A manuscript rejected for Rapid Communications will be automatically reviewed as a regular submission. Authors who do not want their manuscripts to undergo the regular review process after being rejected for Rapid Communications should say so in their cover letters. Authors of a Rapid Communication should submit their manuscript on a computer disk. See "Manuscript Submission."
Reviews: Experimental Hematology publishes Reviews summarizing the present state of knowledge about a particular aspect of a special field. Reviews are peer-reviewed and usually solicited by the editor. Authors interested in writing a Review should first propose the topic to the editorial office.
Letters to the Editor: Letters to the editor may relate to material published in the journal, to ISEH business, editorial policy, or anything else pertinent to the field of experimental hematology. A letter that addresses an article published in this journal should be submitted as soon as possible, no later than two calendar months after publication. Such a letter will be sent to the authors of that paper for a possible reply. All letters and their replies are published at the editor's discretion and are subject to peer-review. Letters should not exceed 1,000 words. Figures and tables cannot be included, and no more than 10 references may be used.
MANUSCRIPT SUBMISSION
Submit four copies of the manuscript (at least one original) and four sets of figures prepared according to the instructions below with the cover letter, statement of authorship, in-press references, permission statements (if applicable), and submission fee to Ronald Hoffman, MD, Editor, at the editorial office address listed at the end of this document.
The manuscript should be formatted according to the instructions under "Manuscript Preparation." Authors who are not fluent in English are advised to seek editorial help before submitting their papers.
Reviewers: In the cover letter accompanying the manuscript, authors are encouraged to suggest several potential reviewers without conflicts of interest, including at least one member of the journal's editoral board.
Requests to not involve a particular expert will not be respected unless a sound reason is specified.
Statement of Authorship: Send with the manuscript the following statement listing the manuscript title and signed by ALL authors: (1) all authors have contributed significantly to the research described in the paper and have read and approved the final manuscript; (2) the manuscript is the original work of the authors except for material in the public domain and such excerpts from other works as may be included with the prior written permission of the copyright owners; (3) neither this manuscript nor another manuscript with substantially similar content under our authorship has been published, has been accepted, or is being considered elsewhere for publication, except as described in an attachment; (4) all affiliations or financial involvement with any entity with a financial interest in the subject matter are completely disclosed and all financial and material support for this research and work are clearly identified in the manuscript; and (5) all individuals who have contributed significantly to the work reported in this manuscript are acknowledged by name and have granted permission to be named.
Computer Disk: Authors of Rapid Communications, letters, and manuscripts that do not contain photographic figures should submit their manuscripts in WordPerfect or Microsoft Word files on 3.5-in. HD/DD computer disks. Make certain that the disk and hard copy match exactly. Specify the software used, including the release (e.g., WordPerfect 6.1) and platform (PC or Macintosh). The article file should include all textual material (text, references, tables, figure captions, etc.), not figures. The file should be single-spaced and should use the wrap-around end-ofline feature (i.e., returns only at the ends of paragraphs). Place two returns after every element, such as title, headings, and paragraphs. Be sure to keep a back-up disk for reference and safety. Disks will not be returned.
Manuscript Length: Write succinctly. Authors are urged to keep the word count of their papers (excluding references, figure legends, and tables) to less than 3,600 words. Longer papers of significant scientific merit will not be excluded from publication, but should still be as concise as possible.
CHARGES TO AUTHORS
Authors pay the following charges:
1. A nonrefundable processing fee of $50 for Regular Submissions ($70 for Rapid Communications). Make checks payable to International Society for Experimental Hematology (ISEH). To pay by credit card, include the following on a separate piece of paper: the title of the article, the type of credit card (Visa, MasterCard, or American Express), the account number and expiration date, the statement "ISEH may charge US$50 (or $70) to my account for the submission fee of this manuscript," the name of the account holder as it appears on the card, and the card holder's signature. Avoid using purchase orders, which are not considered payment until the check arrives at the editorial office. Authors of letters and reviews do not pay submission fees.
2. Page charges for manuscripts: $50 per page for the first five published pages or portions thereof, and $160 for each additional page over five or portion thereof.
3. Expense for color reproduction of figures: $980 per page or portion thereof.
4. Expense for offprints. The publisher will send the corresponding author the price quotation with the page proofs.
MANUSCRIPT PREPARATION
Type manuscripts double-spaced with 10- or 12-point type--including references, figure legends, and tables--on one side of the page only. Type the page number on every page. Leave 1.25-inch margins on all sides, and do not use justified margins. For A4 paper, leave a 2.5-inch margin on the bottom of the page.
Title Page: The first page of the manuscript must include (1) the title (capitalize the initial letter of each word), (2) the full names and academic degrees of all authors, (3) the author's institutional affiliations, (4) the corresponding author?s name, complete mailing address, telephone and fax numbers, and e-mail address, (5) contact information for offprints if different from that of the corresponding author, (6) the Table of Contents category that best describes the manuscript's topic: Cell Cycle Regulation, Clinical Investigations, Cytokines, Erythropoiesis, Gene Transfer/Gene Therapy, General Hematopoiesis, Granulopoiesis, Hematological Malignancies, Immunobiology, Immunotherapy, Lymphopoiesis, Megakaryocytopoiesis, Microenvironment, Monocyte Development, Molecular Genetics, Signal Transduction, Stem Cell Biology, Stem Cell Plasticity, or Stem Cell Transplantation, and (7) the paper?s word count (excluding references, figure legends, and tables).
For manuscripts about clinical studies, use the category of "Clinical Investigation." If your manuscript's topic does not fit within one of these categories, it may not be within the journal?s scope. Contact the editorial office for confirmation.
Abstract: The second page of the manuscript should present an abstract of no more than 250 words under the following headings: (1) Objective, (2) Methods (or Patients and Methods, Materials and Methods, etc.), (3) Results, and (4) Conclusion. Do not cite references.
Text: The body of the paper should begin on the third page and conform to the "Style Guidelines" described below. Do not include a summary at the end of the text. Cite each figure and table in the text in numerical order. Cite each reference in the text in numerical order and list in the References section. In the text, set the reference numbers in brackets. In-text reference numbers may be repeated but not omitted. Authors who are not fluent in English are strongly advised to seek editorial help from a colleague before submitting their papers.
Acknowledgments: List all sources of support for research, plus substantive contributions of individuals. State any potential author conflicts of interest that relate to the manuscript.
References: Include only published materials or those accepted for publication (in press) in the reference list. Cite references in numerical order according to first mention in the text. Verify all entries against original sources, especially journal titles, publication dates, accents, diacritical marks, and spelling in languages other than English.
Journal titles should be abbreviated according to titles listed in Index Medicus. Cite abstracts only if they are the sole source.
Note: The journal's reference style will change in the January 2003 issue. New and revised manuscripts should now incorporate these formats:
1. For a journal article with up to 6 authors, list all authors:
Fraser ST, Ogawa M, Yu RT, Nishikawa S, Yoder MC, Nishikawa SI. Definitive hematopoietic commitment within the embryonic vascular endothelial-caderin+ population. Exp Hematol. 2002;30:1061- 1069.
2. For a journal article with more than 6 authors, list the first 3 authors, followed by et al.:
Berrios VM, Dooner GJ, Nowakowski G, et al. The molecular basis for the cytokine-induced defect in homing and engraftment of hematopoietic stem cells. Exp Hematol. 2001;29:1326-1335.
3. For a journal article in press:
Riley RL, Knowles J, King AM. Levels of E2A protein expression in B cell precursors are stage-dependent and inhibited by stem cell factor (c-kit ligand). Exp Hematol. In press.
4. For a chapter in a book:
Munshi NC, Tricot G, Barlogie B. Plasma cell neoplasms. In: DeVita Jr. VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2491-2493.
5. For an abstract or letter:
Roberts A, Croker B, Handman E, Williams D, Tarlinton D. Rac2 Regulates T and B Lymphocyte Chemotaxis, Distribution and Function [abstract]. Exp Hematol. 2002;30(suppl 1):143. Abstract 427.
For other formats, please follow the recommendations of the International Committee of Medical Journal Editors at http://www.icmje.org/ . Unpublished observations and personal communications cannot be included in the References section, although they may be cited in the text as "(unpublished data, year)." Papers that rely on such citations for details that are essential for critical review of the manuscript may be rejected. For personal communications, the permission of the individual who communicated the data is required.
Figures: Prepare artwork using professional standards and photographed as camera-ready, unmounted, glossy prints if color, halftones, or photomicrographs. Glossy prints of line drawings, graphs, etc. are not required if good quality computer-generated laser prints (not photocopies) are submitted.
Submit four sets of figures: one set of figures created at the highest resolution possible and three sets suitable for reviewers. Photographic figures should not be mounted. Indicate the figure number unobtrusively in the lower right corner of each page containing a line drawing, graph, or other laser-printed art. For photomicrographs, indicate the figure number and the orientation with an arrow on the back. Sort and attach one set of figures to each copy of the manuscript. Submit smaller figures (<8 x 11 in.) in envelopes. Large prints (8.5 x 11 or A4 size) do not require separate envelopes; clip them directly to the manuscript.
Figures that are grouped together must match in size, particularly in height, and be uniform in style and size of lettering.
Supply a scale bar with photomicrographs.
Proofread all text in the figures and ensure that all figure components are clearly distinguishable from each other (e.g., bar graph hatchings).
Ensure that the body of the paper does not repeat data reported in figures.
Figure Legends: Provide double-spaced text for figure legends on separate sheets within the manuscript. Include a title for each figure and define any acronyms, abbreviations, initialisms, or symbols used in the figures.
Tables: Tables should be created using word-processing software (Microsoft Word or Word Perfect). Begin each table on a separate page in double-spaced type. Title the table with "Table" and the Arabic numeral, followed by a period and a brief informative title. Use the same size type as in the text. Indicate footnotes in the table in this order: *, , , ? , , #, **,
Do not use vertical lines in tables. Use horizontal lines above and below the column headings and at the bottom of the table only. Use extra space to delineate sections within the table.
Ensure that the text does not duplicate data reported in tables. Provide a legend defining all acronyms, abbreviations, and initialisms.
Previously Published Material: For manuscripts contaning tables or figures adapted or reproduced from other sources, submit signed statements from both the author and the publisher giving permission to Experimental Hematology for usage. Also, acknowledge the original source in the table or figure legend. Permission is required irrespective of authorship or publisher, except for documents in the public domain.
STYLE GUIDELINES
Abbreviations: All abbreviations must be defined the first time that they are used in the text.
Distribution of reagents: By publishing in this journal, authors imply that they will make freely available to other academic researchers any easily provided materials (e.g., cells, clones of cells, antibodies, DNA probes, nucleic acid sequences, or genetic strains of animals) that were used in the research reported and that are not available from commercial suppliers.
Drugs: Trade names, spelled exactly as trademarked and with the initial letter capitalized, may be used after a drug has been identified once by its generic name or by its systematic chemical name. Unfamiliar compounds other than drugs must also be designated, when first issued, by their correct systematic names. Systematic chemical names should conform to the usage given in the indexes of Chemical Abstracts.
Human Experimentation: In experimental studies with human subjects, details of age, race, and sex of the subject must be included. There must also be a statement that informed consent was obtained from the subjects and that the investigations had been approved by an institutional Human Research Committee. In addition, safeguards for protection of the rights of minors and mentally impaired subjects should be stated. In all material, patients must be identified by number or serial letter and not by initials or names. If the manuscript requires photographs of faces or other identifiable body parts or detailed case descriptions, authors must obtain written consent from the identifiable subject and provide a copy of the permission with the manuscript upon submission.
Manufacturers: Include the name of the pharmaceutical or equipment company, as well as the city, state or province, and country, in parentheses after the first mention of every material used.
Mathematical Notation: Use typewritten letters, numbers, and symbols whenever possible. Identify boldface, script letters, etc., at their first occurrence. Distinguish between one and the letter ?I? and zero and the letter "O" whenever confusion might result.
Any data previously published in any form (except abstracts) must be clearly identified as such.
Measurements: Use metric system and Celsius degrees; use L for liter.
Nomenclature and Symbols: Follow the recommendations of the International Union of Pure and Applied Chemistry (IUPAC) and the International Union of Biochemistry (IUB). In respect to molecular regulators of hemopoiesis that are either essential for proliferation and differentiation of a given cell line or potentiate the action of a specific regulator, sufficient information should be given in respect to its molecular weight, chemical characteristics, stability, resistance to enzymatic digestion, method of asssay, etc., so that others can appreciate the basic properties. When a regulatory molecule has been purified to homogeneity, sequenced, cloned, and produced as a pure entity, the name then given to the humoral regulator should be used. When there are numerous synonyms, these should be listed once. Until there is a consensus in respect to nomenclature, authors may use the names they prefer.
Statistical Analyses: In respect to bioassay or radioimmunoassay, potency estimates should be accompanied by a measure of the precision of these estimates. Both bioassays and radioimmunoassays should be precision- related to within-assay variability and to the variability measurements or subsequent independent assays. When data are insufficient to determine whether the data conform to a normal or other distribution, it is more appropriate to use nonparametric tests of significance. Manuscripts must describe novel methods, models, and approaches to statistical analysis concisely, but in sufficient detail to allow evaluation of the results reported.
Recombinant DNA: With the use of "recombinant" material in research, particularly with recombinant viral vectors that may infect human cells, investigators must include a statement regarding the containment category of genetically engineered organisms. Procedures and safeguards must be specified for the construction and handling of recombinant DNA molecules and organisms and viruses containing recombinant DNA.
COPYRIGHT
All material that is accepted for publication becomes the sole property of the ISEH. Authors must sign a copyright transfer form upon acceptance of any material for publication. The ISEH does, however, grant the authors the right to reproduce tables and figures from their articles published by the ISEH in the author?s future publications.
FOR MORE INFORMATION
Contact Veronica Johnston, the journal's managing editor, at:
Experimental Hematology
University of Illinois at Chicago
900 S. Ashland Ave., M/C 734
Rm. 3150 MBRB
Chicago, IL 60607 USA
E-mail: exphem@uic.edu
Tel: (312) 355-3777
Fax: (312) 355-3778
Editorial Board
Editor-in-Chief:
R. Hoffman MD, Experimental Hematology, University of Illinois at Chicago, 900 South Ashland Avenue, M/C 734, Rm. 3150 MBRB, Chicago, IL 60607, USA; Tel: (312)355-3777, Fax: (312)355-3778, Email: exphem@uic.edu
Managing Editor:
V. Johnston, University of Illinois at Chicago, 900 South Ashland Avenue, M/C 734, Rm. 3150 MBRB, Chicago, IL 60607 USA; Tel: (312)355-3777, Fax: (312)355-3778, Email: exphem@uic.edu
Associate Editors:
A. Bacigalupo MD, Genova, Italy
R.K. Humphries MD, PhD, Vancouver, BC, Canada
L. Kanz MD, Tübingen, Germany
I. McNiece PhD, Baltimore, MD, USA
C. Verfaillie MD, Minneapolis, MN, USA
E. Zanjani PhD, Reno, NV, USA
Past Editors-in-Chief:
L.R. Heim, (1973-1983)
D.R. Boggs, (1984)
M.P. McGarry, (1984-1985)
E.P. Cronkite, (1985-1989)
P.J. Quesenberry, (1990-1998)
Editorial Board:
G. Almeida-Porada, USA
J. Barker, USA
C. Baum, Germany
M. Bhatia, Canada
P. Brossart, Germany
F. Candotti, USA
A.M. Carella, Italy
R. Champlin, USA
D.W. Clapp, USA
A.D. D'Andrea, USA
G. de Haan, The Netherlands
R. Delwel, The Netherlands
V. Duronio, Canada
J.H.F. Falkenburg, The Netherlands
W.H. Fleming, USA
Y. Furukawa, Japan
M.A. Goodell, USA
T. Green, UK
R. Handgretinger, USA
T. Hara, Japan
S. Heimfeld, USA
T.L. Holyoake, UK
A. Karsan, Canada
J.R. Keller, USA
P.W. Kincade, USA
T. Kitamura, Japan
S.P. Klinken, Australia
D. Krause, USA
T. Lapidot, Israel
D.A. Largaespada, USA
T.W. LeBien, USA
D.C. Link, USA
P.P. Liu, USA
P. Malik, USA
K.M. McNagny, Canada
R. Möhle, Germany
K. Moore, USA
A.L. Mui, Canada
C. Muller-Sieburg, USA
W.J. Murphy, USA
T. Nakano, Japan
J.A. Nolta, USA
O.G. Ottmann, Germany
T. Papayannopoulou, USA
W. Piacibello, Italy
F. Prósper, Spain
S. Scheding, Germany
P.J. Simmons, Australia
B.P. Sorrentino, USA
Y. Takihara, Japan
N. Theise, USA
S. Watt, UK
R.S. Weinberg, USA
C. Westbrook, USA
A. Yoshimura, Japan
P. Zandstra, Canada
|
